Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy

被引:1
|
作者
Derosa G. [1 ,4 ]
Cicero A.F.G. [2 ]
D'Angelo A. [1 ]
Tinelli C. [3 ]
Ciccarelli L. [1 ]
Piccinni M.N. [1 ]
Pricolo F. [1 ]
Salvadeo S. [1 ]
Montagna L. [1 ]
Fogari E. [1 ]
Gravina A. [1 ]
Ferrari I. [1 ]
Galli S. [1 ]
Paniga S. [1 ]
Fogari R. [1 ]
机构
[1] Department of Internal Medicine and Therapeutics, University of Pavia, Pavia
[2] 'D. Campanacci' Department of Clinical Medicine and Applied Biotechnology, 'G. Descovich' Atherosclerosis Study Center, University of Bologna, Bologna
[3] Biometric Unit, IRCCS Policlinico S. Matteo, Pavia
[4] Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Piazzale C. Golgi
关键词
Hypertensive Patient; Felodipine; Antihypertensive Treatment; Doxazosin; Fast Plasma Insulin;
D O I
10.2165/00151642-200613020-00002
中图分类号
学科分类号
摘要
Background: There are conflicting data in the literature regarding both the expression pattern of the vascular metalloproteinase (MMP) system and its tissue inhibitors (TIMPs) in human hypertension and the effect of antihypertensive drugs in modifying the MMP/TIMP system. This study was designed to test the hypothesis that MMP-2, MMP-9 and TIMP-1 are altered in hypertension reflecting alterations in extracellular matrix turnover. Moreover, the aim of the study was to assess whether chronic antihypertensive treatment with doxazosin would normalise these alterations. Materials and results: We measured plasma levels and activities of MMP-2, MMP-9 and TIMP-1 in 44 hypertensive patients before and after 4 months of doxazosin treatment. MMP-2 levels and activity were significantly lower in the hypertensive group after treatment (p < 0.0001) compared with respective values before treatment. Significant decrease was also observed for MMP-9 level and activity (p < 0.0001) and for TIMP-1 (p < 0.0001) in hypertensive patients after antihypertensive treatment. Conclusions: Plasma levels and activities of MMP-2, MMP-9 and TIMP-1 are decreased in hypertensive patients after treatment compared with respective values before treatment. This may demonstrate that antihypertensive drugs modify the MMP/TIMP system, contributing to the mechanisms of vascular remodelling. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:47 / 52
页数:5
相关论文
共 50 条
  • [41] Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium
    Chung, HW
    Lee, JY
    Moon, HS
    Hur, SE
    Park, MH
    Wen, Y
    Polan, ML
    [J]. FERTILITY AND STERILITY, 2002, 78 (04) : 787 - 795
  • [42] Serum matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 and heart remodeling in patients with aortic stenosis after operation
    Goncharova, N.
    Moiseeva, O.
    Aleshina, G.
    Shlyakhto, E.
    [J]. JOURNAL OF HYPERTENSION, 2007, 25 : S45 - S45
  • [43] Tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 expression in human amnion mesenchymal and epithelial cells
    Rowe, TF
    King, LA
    MacDonald, PC
    Casey, ML
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 176 (04) : 915 - 921
  • [44] Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 after Administration of Endotoxin in Diabetic Rats
    Seo, Ki Hyun
    Choi, Jae Sung
    Na, Joo Ok
    Uh, Soo Taek
    Kim, Yong Hoon
    Park, Choon Sik
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2006, 61 (03) : 256 - 264
  • [45] Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients
    Duda, Izabela
    Krzych, Lukasz
    Jedrzejowska-Szypulka, Halina
    Lewin-Kowalik, Joana
    [J]. OPEN MEDICINE, 2020, 15 (01): : 50 - 56
  • [46] CELL DISTRIBUTION DIFFERENCES OF MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE-1 IN PATIENTS WITH KAWASAKI DISEASE
    Korematsu, Seigo
    Ohta, Yoko
    Tamai, Naotaka
    Takeguchi, Masahiro
    Goto, Chika
    Miyahara, Hiroaki
    Kawano, Tatsuya
    Izumi, Tatsuro
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (09) : 973 - 974
  • [47] Expression of Type IV Collagen, Metalloproteinase-2, Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Laryngeal Squamous Cell Carcinomas
    Cao, Xiao-Lin
    Xu, Ru-Jun
    Zheng, You-Yang
    Liu, Jun
    Teng, Yao-Shu
    Li, Yong
    Zhu, Jin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3245 - 3249
  • [48] Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1: a possible role in the pathogenesis of endometriosis
    Szamatowicz, J
    Laudanski, P
    Tomaszewska, I
    [J]. HUMAN REPRODUCTION, 2002, 17 (02) : 284 - 288
  • [49] Secretion of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and human chorionic gonadotropin by cytotrophoblastic cells: Is there a regulation by relaxin?
    Mock, P
    Meisser, A
    Araman, M
    Wuillemin, C
    Campana, A
    Bischof, P
    [J]. RELAXIN 2000, 2001, : 121 - 125
  • [50] Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in adenomyosis
    Yang, Jehn-Hsiahn
    Wu, Ming-Yih
    Chen, Mei-Jou
    Chen, Shee-Uan
    Yang, Yu-Shih
    Ho, Hong-Nerng
    [J]. FERTILITY AND STERILITY, 2009, 91 (05) : 2193 - 2198